We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Diagnostic Microchip Inserted Under Skin Can Detect COVID-19

By LabMedica International staff writers
Posted on 14 Apr 2021
Researchers have created a microchip that can detect COVID-19 when inserted under the skin.

The implantable microchip developed by medical researchers at the US Pentagon’s Defense Advanced Research Projects Agency (DARPA; Arlington, VA, USA) can monitor the human body for signs of the SARS-CoV-2 virus. More...
Details of the revolutionary technology were shared on the 60 Minutes Show by Matthew Hepburn, an infectious disease physician and retired Army colonel who is heading DARPA’s response to the pandemic.

Hepburn told CBS that the microchip, embedded in a tissue-like gel, would continuously test the chip recipient’s blood for presence of the coronavirus. Upon detecting COVID-19, the chip would alert the patient to conduct a self-administered rapid blood test to confirm the positive result. According to Hepburn, DARPA had also developed a filter to remove the SARS-CoV-2 virus from the blood through a dialysis machine. The filter had been approved by the US Food and Drug Administration (FDA) and had already been used on 300 patients. Additionally, Hepburn compared the diagnostic microchip to a car’s “Check engine” alert and assured that DARPA’s chip would neither “track your every move” nor be administered via vaccines.

“It’s a sensor,” Hepburn told CBS. “That tiny green thing in there, you put it underneath your skin and what that tells you is that there are chemical reactions going on inside the body and that signal means you are going to have symptoms tomorrow. We can have that information in three to five minutes. As you truncate that time, as you diagnose and treat, what you do is you stop the infection in its tracks.”

Related Links:
Defense Advanced Research Projects Agency (DARPA)


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Online QC Software
Acusera 24•7
Electrolyte Analyzer
CBS-4000 (CBS-400)
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.